| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
FPH2 (also known as BRD-9424) is able to promote differentiation of iPS-derived hepatocytes. In vitro, FPH2 induced functional proliferation of hepatocytes and might be useful for expanding mature human primary hepatocytes. In human primary hepatocytes, FPH2 increased the number of nuclei undergoing mitosis and hepatocyte nuclei count in a concentration dependent way. Also, FPH2 (40 μM) increased the area of hepatocyte colonies with more hepatocytes and Ki67-positive nuclei, which exhibited hepatocyte nuclear morphologies. In primary human hepatocytes from six additional cell sources, FPH2 increased hepatocytes expansion. FPH2 increased hepatocyte at a rate that is consistent with liver regeneration kinetics in vivo.
| ln Vitro |
FPH2 may be helpful for growing mature human primary hepatocytes since it causes functional proliferation of hepatocytes in vitro. During primary screening, FPH1 and FPH2 can increase the number of hepatocyte nuclei and/or increase the number of nuclei undergoing mitosis. These effects on hepatocytes are concentration dependant. FPH1 and FPH2-treated cells continue to perform liver-specific tasks. FPH2 doubles the rate of hepatocyte induction over 7 days, which is in line with the kinetics of liver regeneration that have been documented in vivo[1].
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
[1]. Shan J, et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol. 2013 Aug;9(8):514-20.
|
||
| Additional Infomation |
4-[[(5-chloro-2-methoxyanilino)-sulfanylidenemethyl]amino]-1-ethyl-3-pyrazolecarboxamide is a member of thioureas.
|
| Molecular Formula |
C14H16CLN5O2S
|
|
|---|---|---|
| Molecular Weight |
353.83
|
|
| Exact Mass |
353.071
|
|
| CAS # |
957485-64-2
|
|
| Related CAS # |
|
|
| PubChem CID |
2208391
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| Density |
1.45±0.1 g/cm3
|
|
| LogP |
3.319
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
23
|
|
| Complexity |
441
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(C1C(NC(NC2C(OC)=CC=C(Cl)C=2)=S)=CN(CC)N=1)N
|
|
| InChi Key |
PCHRYHSDDPPZBV-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C14H16ClN5O2S/c1-3-20-7-10(12(19-20)13(16)21)18-14(23)17-9-6-8(15)4-5-11(9)22-2/h4-7H,3H2,1-2H3,(H2,16,21)(H2,17,18,23)
|
|
| Chemical Name |
4-[[[(5-chloro-2-methoxyphenyl)amino]thioxomethyl]amino]-1-ethyl-1H-pyrazole-3-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8262 mL | 14.1311 mL | 28.2622 mL | |
| 5 mM | 0.5652 mL | 2.8262 mL | 5.6524 mL | |
| 10 mM | 0.2826 mL | 1.4131 mL | 2.8262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05482594 | RECRUITING | Diagnostic Test:ELISA Diagnostic Test:Videocapillaroscopy |
Systemic Sclerosis | Brugmann University Hospital | 2022-01-11 | |
| NCT00434239 | UNKNOWN STATUS | Drug:Lenalidomide+Ancestim | Myelodysplasia | Peter MacCallum Cancer Centre, Australia |
2007-02 | Early Phase 1 |
| NCT00001398 | COMPLETED | Drug:Recombinant Methionyl Huma Stem Cell Factor(r-metHuSCF) |
Aplastic Anemia Pancytopenia |
National Heart,Lung, Blood Institute(NHLBI) |
1993-10 | Phase 1 |
| NCT00005783 | COMPLETED | Drug:Recombinant-methionyl human stem cell factor |
Hemoglobin SC Disease Sickle Cell Anemia |
National Institute of Diabetes Digestive and Kidney Diseases (NIDDK) |
2000-03 | Phase 1 |
| NCT00058045 | COMPLETED | Biological:aldesleukin Biological:recombinant human stem cell factor |
Lymphoma | Roswell Park Cancer Institute | 2002-08 | Phase 1 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
